Three Arch Partners

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients suffering from acute and chronic liver diseases, addressing a significant unmet medical need. The company's lead product, OCR-002, functions as an ammonia scavenger and is being investigated in both intravenous and oral formulations to treat hyperammonemia. Recently, Ocera completed a Phase 2b clinical trial named STOP-HE, which assessed the safety and efficacy of intravenously administered OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera is currently preparing for a meeting with the FDA to discuss the intravenous program and explore potential development pathways for its therapeutics.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

MEI Pharma, Inc. is a late-stage pharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for cancer treatment. The company's clinical pipeline includes several key drug candidates such as Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor currently in Phase II trials for relapsed follicular lymphoma, and Voruciclib, an oral cyclin-dependent kinase inhibitor under investigation for acute myeloid leukemia and B-cell malignancies in Phase Ib trials. Additionally, MEI Pharma is developing ME-344, a mitochondrial inhibitor targeting HER2-negative breast cancer, and Pracinostat, an oral histone deacetylase inhibitor being tested for myelodysplastic syndrome. The company has established various collaborations and agreements with notable partners, including Kyowa Kirin Company and BeiGene, to support its clinical development efforts. Founded in 2000, MEI Pharma has evolved significantly since its inception and continues to focus on advancing its promising oncology therapies.

Access Closure, Inc. is a medical device company based in Mountain View, California, specializing in vascular closure solutions for interventional and diagnostic procedures. Founded in 2002, the company offers innovative products, including the Mynx delivery system. This device effectively seals arteriotomy sites using a water-soluble and extravascular sealant, which expands within the tissue by absorbing blood and subcutaneous fluids. Access Closure aims to simplify and enhance the process of vascular closure, addressing the complexities associated with these medical procedures.

iScience Interventional specializes in the discovery and development of microcatheter and imaging technologies aimed at enhancing ophthalmic care. The company focuses on a novel approach termed Interventional Ophthalmology, which involves microcatheter-based therapies that allow ophthalmologists to access various anatomical structures within the eye. These technologies facilitate the aspiration of ocular fluids and the delivery of sterile ophthalmic solutions, enabling targeted treatment for a range of ocular diseases. Additionally, iScience Interventional provides medical devices specifically designed for canaloplasty procedures, further contributing to advancements in the management of eye conditions.

Access Closure, Inc. is a medical device company based in Mountain View, California, specializing in vascular closure solutions for interventional and diagnostic procedures. Founded in 2002, the company offers innovative products, including the Mynx delivery system. This device effectively seals arteriotomy sites using a water-soluble and extravascular sealant, which expands within the tissue by absorbing blood and subcutaneous fluids. Access Closure aims to simplify and enhance the process of vascular closure, addressing the complexities associated with these medical procedures.

Inova Labs, Inc. is a medical device development and manufacturing company based in Austin, Texas, established in 2002. The company specializes in creating innovative direct patient care products, particularly focusing on respiratory support. Its flagship offerings include the LifeChoice oxygen concentrators, which are available in both stationary and portable models, designed to provide supplemental oxygen for patients with respiratory illnesses. The LifeChoice products feature a pulse mode system and cater to various oxygen flow needs. Inova Labs also provides essential accessories such as carrying cases, external batteries, and power adapters. The company's products are distributed through authorized providers, who sell them on their respective websites.

Salveo Specialty Pharmacy is an independent pharmacy that specializes in providing medications and clinical services to patients with chronic conditions. With a commitment to enhancing the wellness and health of its patients, Salveo works closely with customers, referral sources, and insurance plans to ensure effective communication and superior patient care. The company combines its expertise in specialty pharmacy, home infusion, and home healthcare to deliver comprehensive clinical support tailored to the needs of individuals managing long-term health issues.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

Crux Biomedical, Inc., established in August 2004 by physicians Tom Fogarty and Frank Arko, focuses on developing innovative medical devices to address the limitations of existing vena cava filters. The company's primary product, the Crux VCF System, serves as a preventive device for pulmonary embolisms, effectively stopping blood clots from reaching the lungs. This system is particularly beneficial for patients at risk of pulmonary embolism who are unable to tolerate blood thinners, providing a vital method for preventing potentially life-threatening clots.

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

Tibion Bionic Technologies is a medical device company based in Moffett Field, California, specializing in the design and development of bionic devices aimed at enhancing mobility for individuals with impairments. Founded in 2002, the company focuses on creating non-invasive technologies that support rehabilitation for those recovering from surgeries, strokes, or experiencing age-related decline in muscle function. One of its notable products, PowerKnee, is a wearable bionic device designed to aid leg rehabilitation, improve muscle strength, and assist users in daily activities. Tibion's innovations integrate advancements in orthotics, biomechanics, and control systems to provide effective solutions for mobility-impaired individuals, while actively supporting rehabilitation efforts for those with lower extremity dysfunction.

VisionCare Ophthalmic Technologies, Inc. is a specialty medical device company based in Saratoga, California, focused on the research, development, manufacture, and marketing of innovative implantable ophthalmic devices. The company primarily aims to enhance vision and quality of life for individuals suffering from untreatable retinal disorders, particularly end-stage age-related macular degeneration (AMD), which is a leading cause of blindness among older Americans. VisionCare's flagship product is the Implantable Miniature Telescope, the first FDA-approved device designed to improve vision in patients with advanced AMD. This telescope implant is a critical component of the CentraSight treatment program, which guides patients through the processes of diagnosis, surgical evaluation, and postoperative care. Founded in 1997, VisionCare is dedicated to helping patients reconnect with their daily lives and activities through its advanced visual prosthetic technologies.

TriReme Medical, Inc. is a privately held medical device company located in Pleasanton, California, established in 2005. The company focuses on the development and manufacturing of innovative stent technologies aimed at treating coronary artery disease, particularly in complex areas such as bifurcations. TriReme Medical specializes in advanced therapeutic technology systems for both coronary and peripheral vascular diseases. Its next-generation percutaneous devices, including novel balloon and stent therapies, address significant clinical needs in these markets, offering physicians differentiated tools to enhance patient outcomes in challenging vascular interventions.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Ingenuity Systems is a software platform designed to support life science researchers by providing access to crucial information services. The platform allows enterprise customers to facilitate the use of internal portals, search engines, and various software tools, enabling researchers to efficiently search, explore, visualize, and analyze biological and chemical data related to genes, proteins, and small molecules. By streamlining access to these resources, Ingenuity Systems enhances the research capabilities of its users, ultimately contributing to advancements in the life sciences field.

Calistoga Pharmaceuticals, Inc. focuses on developing innovative oral therapeutics that target specific isoforms of the PI3 kinase pathway, which plays a crucial role in cell survival and immune responses. The company's approach aims to enhance treatment outcomes for patients suffering from cancer and inflammatory diseases while minimizing adverse effects. Its lead product, CAL-101, is an oral inhibitor selectively targeting the delta isoform of PI3K, showing promising clinical responses in patients with B-cell malignancies and undergoing various clinical trials. Beyond CAL-101, Calistoga Pharmaceuticals has a pipeline of additional selective PI3K inhibitors that are either in early preclinical stages or poised for initial clinical trials, further advancing its commitment to addressing cancer and inflammatory conditions.

Baxano, Inc. specializes in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in areas such as the foramen, lateral recess, and central canal, catering to patients with varying degrees of stenosis. Its product line includes the Neuro Check device, which enables surgeons to verify that the device is positioned against the bone with the nerve safely out of the way. Additionally, Baxano provides the MicroBlade Shaver instrument for the removal of impinging bone and ligament, along with essential tools like guidewires, probes, and distal handles. Founded in 2005, Baxano continues to innovate in the field of spinal health.

Voyage Medical, Inc. is a company that specializes in the manufacturing of cardiac medical devices aimed at treating atrial fibrillation, a common heart rhythm disorder. Established in 2006, the company is located in Redwood City, California. Voyage Medical focuses on developing innovative solutions to improve patient outcomes in the field of cardiology.

Hemosphere developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction.

Access Closure, Inc. is a medical device company based in Mountain View, California, specializing in vascular closure solutions for interventional and diagnostic procedures. Founded in 2002, the company offers innovative products, including the Mynx delivery system. This device effectively seals arteriotomy sites using a water-soluble and extravascular sealant, which expands within the tissue by absorbing blood and subcutaneous fluids. Access Closure aims to simplify and enhance the process of vascular closure, addressing the complexities associated with these medical procedures.

Free & Clear, Inc. specializes in phone-based tobacco treatment services aimed at employers, health plans, and government agencies. The company provides a comprehensive tobacco cessation program, known as the Quit For Life Program, which assists employees and members of private organizations in quitting smoking and using smokeless tobacco. Additionally, Free & Clear offers the Mind & Body Program, a behavioral change initiative designed to promote healthy weight management and address health risks associated with chronic diseases, such as tobacco use, poor nutrition, and physical inactivity. By delivering these clinically proven solutions, Free & Clear aims to support individuals in achieving healthier lifestyles.

Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

Visiogen, Inc. is an ophthalmic medical device company focused on developing innovative vision solutions for patients with cataracts, including those with presbyopia. The company's flagship product is the Synchrony dual optic accommodating intraocular lens (IOL), designed to deliver a seamless range of near, intermediate, and distance vision without the need for glasses or contact lenses. This advanced device is supplied in a pre-loaded injector to minimize lens handling during surgical procedures. Visiogen's technology has received CE Mark approval in Europe and is currently in clinical trials in the United States, aiming to enhance the quality of life for cataract patients through improved vision correction options.

iScience Interventional specializes in the discovery and development of microcatheter and imaging technologies aimed at enhancing ophthalmic care. The company focuses on a novel approach termed Interventional Ophthalmology, which involves microcatheter-based therapies that allow ophthalmologists to access various anatomical structures within the eye. These technologies facilitate the aspiration of ocular fluids and the delivery of sterile ophthalmic solutions, enabling targeted treatment for a range of ocular diseases. Additionally, iScience Interventional provides medical devices specifically designed for canaloplasty procedures, further contributing to advancements in the management of eye conditions.

Calistoga Pharmaceuticals, Inc. focuses on developing innovative oral therapeutics that target specific isoforms of the PI3 kinase pathway, which plays a crucial role in cell survival and immune responses. The company's approach aims to enhance treatment outcomes for patients suffering from cancer and inflammatory diseases while minimizing adverse effects. Its lead product, CAL-101, is an oral inhibitor selectively targeting the delta isoform of PI3K, showing promising clinical responses in patients with B-cell malignancies and undergoing various clinical trials. Beyond CAL-101, Calistoga Pharmaceuticals has a pipeline of additional selective PI3K inhibitors that are either in early preclinical stages or poised for initial clinical trials, further advancing its commitment to addressing cancer and inflammatory conditions.

SpinalMotion is a private company focused on preserving spinal motion for patients suffering from degenerative disc disease. Founded in 2004, the company specializes in the development of innovative artificial disc implants that utilize proprietary Kineflex Technology, designed to maintain the natural movement of the spine while offering low wear and improved longevity. Since obtaining FDA approval in 2005 to conduct clinical trials for lumbar and cervical artificial discs in the United States, SpinalMotion has built on its international clinical experience to enhance patient outcomes. The company has attracted investment from notable partners, including Southern Medical, Three Arch Partners, Skyline Ventures, and MedVenture Associates, to further its mission of enabling patients to lead pain-free and healthy lives.

WaveRx, Inc. went out of business. WaveRx, Inc. operates as a medical device company that develops technologies and products for dermatological disorders of the nail and skin. WaveRx, Inc. was formerly known as ID Wave Systems and changed its name to WaveRx, Inc. in October 2005. The company was incorporated in 2004 and is based in Waltham, Massachusetts.

Arete Therapeutics is a pharmaceutical company that develops small molecule therapeutics for diabetes and cardiovascular disease.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

Baxano, Inc. specializes in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in areas such as the foramen, lateral recess, and central canal, catering to patients with varying degrees of stenosis. Its product line includes the Neuro Check device, which enables surgeons to verify that the device is positioned against the bone with the nerve safely out of the way. Additionally, Baxano provides the MicroBlade Shaver instrument for the removal of impinging bone and ligament, along with essential tools like guidewires, probes, and distal handles. Founded in 2005, Baxano continues to innovate in the field of spinal health.

Voyage Medical, Inc. is a company that specializes in the manufacturing of cardiac medical devices aimed at treating atrial fibrillation, a common heart rhythm disorder. Established in 2006, the company is located in Redwood City, California. Voyage Medical focuses on developing innovative solutions to improve patient outcomes in the field of cardiology.

Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.

Eleme Medical, Inc. is a venture-backed aesthetics company focused on innovative body shaping technologies. Its flagship product, SmoothShapes® XV, enhances cellulite treatment and offers advanced protocols for pre- and post-liposuction care. This system features increased laser power and user-friendly treatment guidance, making it a valuable addition to aesthetic practices. Both SmoothShapes XV and its predecessor, launched in 2008, utilize the proprietary Photomology® platform, which combines light and laser energy with mechanical manipulation to effectively address cellulite and subcutaneous fat. These FDA-cleared devices provide long-lasting results for patients. Eleme Medical targets plastic surgeons, aesthetic dermatologists, medical spas, and other aesthetic professionals, capitalizing on the growing demand in the body shaping sector of the aesthetics market.

Cameron Health, Inc. is a development-stage medical device company focused on creating advanced implantable electronic devices aimed at improving patient care in the field of cardiac health. The company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems designed for patients at risk of life-threatening ventricular tachyarrhythmias. Their product line includes the SQ-RX pulse generator, which is essential for managing cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, designed for optimal placement within the body. Additionally, the Q-TECH programmer enables wireless communication with the SQ-RX device, enhancing device functionality. Cameron Health's mission is to address unmet medical needs through innovative technology, leveraging the expertise of its team to tackle complex medical challenges.

NovaSys Health is a prominent provider of managed healthcare services, operating one of the largest health plans in Arkansas. With approximately 11,000 contracted providers in the region and over 4,300 in Arkansas, the company emphasizes strong relationships with healthcare providers. It offers a range of health plans and related services, including customized solutions, provider relations, and eligibility and billing administration, catering to a diverse network of hospitals, physicians, and ancillary providers.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs for autoimmune and central nervous system disorders. The company employs an innovative precision deuterium chemistry platform to enhance the properties of established drug molecules, which enables the creation of new chemical entities with potential efficacy and safety advantages. Notable product candidates include CTP-543, currently in Phase III trials for alopecia areata, CTP-692 for schizophrenia in Phase II trials, and AVP-786, which targets neurological and psychiatric disorders in Phase III trials. Concert Pharmaceuticals also engages in strategic collaborations with various pharmaceutical companies to support its development efforts. Founded in 2006 and based in Lexington, Massachusetts, the company aims to streamline research and development processes, reducing associated risks and costs while advancing its therapeutic pipeline.

Spiration, Inc., operating as Olympus Respiratory America, specializes in the development of medical devices aimed at treating air leaks and lung diseases. Founded in 1999 and headquartered in Redmond, Washington, the company focuses on innovative solutions for both acute and chronic lung conditions. One of its key products is the IBV valve system, a minimally invasive device designed to redirect airflow from diseased sections of the lung to healthier areas. This system is particularly beneficial for patients suffering from emphysema, prolonged air leaks, and other complications associated with damaged lungs. As of 2010, Spiration operates as a subsidiary of Olympus America Inc.

Arbor Surgical Technologies, Inc. located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery.

North American Scientific is engaged in the design, development, manufacture, and sale of radioisotopic products for the treatment of cancer. The company offers Prospera I-125, an iodine-based seed and Prospera Pd-103, a palladium-based seed for the treatment of prostate cancer; SurTRAK needles and strands used primarily for the treatment of prostate cancer; and STP-110 Precision Stepper and RTP-6000 Precision Stabilizer equipment, which positions and holds the trans-rectal ultrasound probe during the LDR brachytherapy procedure as well as radiation shielding and needle loading accessories such as horizontal needle box; and needle-loading shield, box, and carousel. The company also offers ClearPath, a multi-catheter breast brachytherapy device for accelerated partial breast irradiation treatment for women with early-stage breast cancer. North American Scientific was founded in 1987 and is based in Chatsworth, California, United States.

Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.

Calistoga Pharmaceuticals, Inc. focuses on developing innovative oral therapeutics that target specific isoforms of the PI3 kinase pathway, which plays a crucial role in cell survival and immune responses. The company's approach aims to enhance treatment outcomes for patients suffering from cancer and inflammatory diseases while minimizing adverse effects. Its lead product, CAL-101, is an oral inhibitor selectively targeting the delta isoform of PI3K, showing promising clinical responses in patients with B-cell malignancies and undergoing various clinical trials. Beyond CAL-101, Calistoga Pharmaceuticals has a pipeline of additional selective PI3K inhibitors that are either in early preclinical stages or poised for initial clinical trials, further advancing its commitment to addressing cancer and inflammatory conditions.

SquareOne is a content creation platform designed to support established personalities and content creators in the gaming industry. The company understands the unique needs of its partners and offers tailored assistance that emphasizes high-quality service over a broad reach. By providing professional support in areas such as revenue opportunities, brand growth, and technical guidance, SquareOne enables creators to thrive in a competitive landscape. The focus on individualized support helps creators to continue their growth and success in the gaming sector.

TriReme Medical, Inc. is a privately held medical device company located in Pleasanton, California, established in 2005. The company focuses on the development and manufacturing of innovative stent technologies aimed at treating coronary artery disease, particularly in complex areas such as bifurcations. TriReme Medical specializes in advanced therapeutic technology systems for both coronary and peripheral vascular diseases. Its next-generation percutaneous devices, including novel balloon and stent therapies, address significant clinical needs in these markets, offering physicians differentiated tools to enhance patient outcomes in challenging vascular interventions.

Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety, Inc. was founded in 2000 through a collaboration of medical device incubators Thomas Fogarty Engineering and The Foundry, and is headquartered in Palo Alto, California.

Arete Therapeutics is a pharmaceutical company that develops small molecule therapeutics for diabetes and cardiovascular disease.

NeuroVista Corporation is a medical device company based in Seattle, Washington, focused on developing innovative technologies for the management and treatment of epilepsy, a condition impacting approximately 3 million individuals in the United States. The company provides advisory technologies designed to reduce the uncertainty surrounding the onset of epileptic seizures, which can vary in severity from brief lapses of awareness to severe convulsions. Founded in 2002 and originally known as BioNeuronics Corporation, NeuroVista rebranded in 2007 to emphasize its commitment to addressing the challenges faced by those affected by epilepsy, a neurological disorder that predominantly affects individuals aged 15 to 64.

Pegasus Biologics, Inc. engages in manufacturing, developing, and marketing bioimplants for soft tissue repair and wound care for diabetic ulcers. Its products include OrthADAPT Bioimplant, which is an organized tissue scaffold that used for the repair and reinforcement of soft tissues, such as tendons and ligaments; and Unite Biomatrix, which is an enzyme resistant collagen scaffold that allows for suture retention and intrinsic strength. The company serves orthopedics, sports medicine, neurosurgical, and spine applications. Pegasus Biologics, Inc. was founded in 2003 and is based in Irvine, California. As of July 17, 2009, Pegasus Biologics, Inc. operates as a subsidiary of Synovis Life Technologies Inc.

Reliant Technologies specializes in advanced laser treatments, particularly focusing on their proprietary Fraxel™ Laser Treatment. Founded in 2001 by a team of leading laser scientists, clinicians, and business executives, the company aims to redefine the standards of care in dermatology. Reliant's innovative technology platform addresses the challenges associated with aging and sun-damaged skin, moving beyond traditional, bulky laser systems. The company is committed to delivering effective solutions that enhance patient outcomes and streamline the treatment process, establishing a new paradigm in laser medicine.

iScience Interventional specializes in the discovery and development of microcatheter and imaging technologies aimed at enhancing ophthalmic care. The company focuses on a novel approach termed Interventional Ophthalmology, which involves microcatheter-based therapies that allow ophthalmologists to access various anatomical structures within the eye. These technologies facilitate the aspiration of ocular fluids and the delivery of sterile ophthalmic solutions, enabling targeted treatment for a range of ocular diseases. Additionally, iScience Interventional provides medical devices specifically designed for canaloplasty procedures, further contributing to advancements in the management of eye conditions.

Aspen Medtech, a Bellevue, WA-based medical device incubator.

Ascend Health Corporation is a behavioral healthcare provider that specializes in a comprehensive range of inpatient and day hospital services for individuals across various age groups, including children, adolescents, adults, and seniors. The organization operates freestanding psychiatric hospitals and offers a wide array of behavioral health programs, such as residential treatment centers, partial hospitalization, and intensive outpatient services. Ascend Health emphasizes personal choice and tailored care, ensuring that its services are effectively integrated with the local healthcare systems to deliver high-quality treatment for mental health and substance abuse issues.

SquareOne is a content creation platform designed to support established personalities and content creators in the gaming industry. The company understands the unique needs of its partners and offers tailored assistance that emphasizes high-quality service over a broad reach. By providing professional support in areas such as revenue opportunities, brand growth, and technical guidance, SquareOne enables creators to thrive in a competitive landscape. The focus on individualized support helps creators to continue their growth and success in the gaming sector.

SmoothShapes Inc., a Merrimack, N.H.-based aesthetics company.

Calistoga Pharmaceuticals, Inc. focuses on developing innovative oral therapeutics that target specific isoforms of the PI3 kinase pathway, which plays a crucial role in cell survival and immune responses. The company's approach aims to enhance treatment outcomes for patients suffering from cancer and inflammatory diseases while minimizing adverse effects. Its lead product, CAL-101, is an oral inhibitor selectively targeting the delta isoform of PI3K, showing promising clinical responses in patients with B-cell malignancies and undergoing various clinical trials. Beyond CAL-101, Calistoga Pharmaceuticals has a pipeline of additional selective PI3K inhibitors that are either in early preclinical stages or poised for initial clinical trials, further advancing its commitment to addressing cancer and inflammatory conditions.

Visiogen, Inc. is an ophthalmic medical device company focused on developing innovative vision solutions for patients with cataracts, including those with presbyopia. The company's flagship product is the Synchrony dual optic accommodating intraocular lens (IOL), designed to deliver a seamless range of near, intermediate, and distance vision without the need for glasses or contact lenses. This advanced device is supplied in a pre-loaded injector to minimize lens handling during surgical procedures. Visiogen's technology has received CE Mark approval in Europe and is currently in clinical trials in the United States, aiming to enhance the quality of life for cataract patients through improved vision correction options.

AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.

NBI Development is an implantable medical device company focused on the development of novel neuromodulation therapies. The company develops neuromodulation, the use of electrical impulses to manage activity in the nervous system.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs for autoimmune and central nervous system disorders. The company employs an innovative precision deuterium chemistry platform to enhance the properties of established drug molecules, which enables the creation of new chemical entities with potential efficacy and safety advantages. Notable product candidates include CTP-543, currently in Phase III trials for alopecia areata, CTP-692 for schizophrenia in Phase II trials, and AVP-786, which targets neurological and psychiatric disorders in Phase III trials. Concert Pharmaceuticals also engages in strategic collaborations with various pharmaceutical companies to support its development efforts. Founded in 2006 and based in Lexington, Massachusetts, the company aims to streamline research and development processes, reducing associated risks and costs while advancing its therapeutic pipeline.

Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

LipoScience, based in Raleigh, North Carolina, specializes in developing in vitro diagnostic tests utilizing nuclear magnetic resonance (NMR) technology. The company's flagship product, the NMR LipoProfile test, quantifies low density lipoprotein particles (LDL-P) in blood samples, offering crucial insights for physicians and patients to tailor heart disease risk management. With more than 8 million tests ordered, LipoScience is at the forefront of personalized diagnostics, providing actionable data that enhances patient care and treatment strategies.

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs for autoimmune and central nervous system disorders. The company employs an innovative precision deuterium chemistry platform to enhance the properties of established drug molecules, which enables the creation of new chemical entities with potential efficacy and safety advantages. Notable product candidates include CTP-543, currently in Phase III trials for alopecia areata, CTP-692 for schizophrenia in Phase II trials, and AVP-786, which targets neurological and psychiatric disorders in Phase III trials. Concert Pharmaceuticals also engages in strategic collaborations with various pharmaceutical companies to support its development efforts. Founded in 2006 and based in Lexington, Massachusetts, the company aims to streamline research and development processes, reducing associated risks and costs while advancing its therapeutic pipeline.

Cameron Health, Inc. is a development-stage medical device company focused on creating advanced implantable electronic devices aimed at improving patient care in the field of cardiac health. The company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems designed for patients at risk of life-threatening ventricular tachyarrhythmias. Their product line includes the SQ-RX pulse generator, which is essential for managing cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, designed for optimal placement within the body. Additionally, the Q-TECH programmer enables wireless communication with the SQ-RX device, enhancing device functionality. Cameron Health's mission is to address unmet medical needs through innovative technology, leveraging the expertise of its team to tackle complex medical challenges.

Concuity is a prominent provider of revenue cycle management software and services, focusing on contract profitability, compliance, denial management, and overall revenue process improvement for healthcare organizations. The company offers a fully web-based and scalable solution that enables these organizations to gain visibility and control over their revenue management processes. By facilitating the creation and negotiation of fair contracts, ensuring compliance with contractual obligations, and assisting in the identification and recovery of underpaid and denied accounts, Concuity enhances the efficiency of revenue management. Their solutions are customized to incorporate unique business rules and payer terms, allowing clients to better manage their revenue throughout its lifecycle.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Spiration, Inc., operating as Olympus Respiratory America, specializes in the development of medical devices aimed at treating air leaks and lung diseases. Founded in 1999 and headquartered in Redmond, Washington, the company focuses on innovative solutions for both acute and chronic lung conditions. One of its key products is the IBV valve system, a minimally invasive device designed to redirect airflow from diseased sections of the lung to healthier areas. This system is particularly beneficial for patients suffering from emphysema, prolonged air leaks, and other complications associated with damaged lungs. As of 2010, Spiration operates as a subsidiary of Olympus America Inc.

Reliant Technologies specializes in advanced laser treatments, particularly focusing on their proprietary Fraxel™ Laser Treatment. Founded in 2001 by a team of leading laser scientists, clinicians, and business executives, the company aims to redefine the standards of care in dermatology. Reliant's innovative technology platform addresses the challenges associated with aging and sun-damaged skin, moving beyond traditional, bulky laser systems. The company is committed to delivering effective solutions that enhance patient outcomes and streamline the treatment process, establishing a new paradigm in laser medicine.

Habit OPCO is a healthcare company that specializes in providing medication-assisted treatment services for individuals struggling with opiate addiction. Operating from 20 established locations and two mobile units across Massachusetts, Vermont, New Jersey, New Hampshire, and Pennsylvania, the company offers a combination of medication and counseling to support recovery. Habit OPCO is dedicated to addressing the challenges of opiate addiction by delivering comprehensive care tailored to the needs of its patients.

Oculir develops non-invasive glucose meter that measures glucose from the conjunctiva of the eye.

Cameron Health, Inc. is a development-stage medical device company focused on creating advanced implantable electronic devices aimed at improving patient care in the field of cardiac health. The company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems designed for patients at risk of life-threatening ventricular tachyarrhythmias. Their product line includes the SQ-RX pulse generator, which is essential for managing cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, designed for optimal placement within the body. Additionally, the Q-TECH programmer enables wireless communication with the SQ-RX device, enhancing device functionality. Cameron Health's mission is to address unmet medical needs through innovative technology, leveraging the expertise of its team to tackle complex medical challenges.

Radiant Medical is a private medical device company based in Redwood City, California, established in 1999. The company specializes in endovascular temperature therapy, focusing on the treatment of heart, brain, and kidney disorders. Its primary product is a single-use central venous heat exchange balloon catheter, which works in conjunction with a heat exchange cassette, a microprocessor-driven controller, and an integrated temperature sensor. This innovative system allows for the safe and rapid reduction, maintenance, and warming of a patient’s core body temperature, enhancing treatment efficacy in critical care settings.

Centerre Healthcare Corporation, founded in 2002 and based in Brentwood, Tennessee, operates rehabilitation hospitals that focus on comprehensive care for patients recovering from various conditions. The organization offers specialized inpatient rehabilitation services for individuals dealing with strokes, brain injuries, spinal cord injuries, burns, traumatic injuries, and orthopedic issues such as hip and knee replacements. Centerre Healthcare is dedicated to addressing the medical, psychological, social, and functional needs of its patients, aiming to support their independence and enhance their quality of life following injury or illness.

Pegasus Biologics, Inc. engages in manufacturing, developing, and marketing bioimplants for soft tissue repair and wound care for diabetic ulcers. Its products include OrthADAPT Bioimplant, which is an organized tissue scaffold that used for the repair and reinforcement of soft tissues, such as tendons and ligaments; and Unite Biomatrix, which is an enzyme resistant collagen scaffold that allows for suture retention and intrinsic strength. The company serves orthopedics, sports medicine, neurosurgical, and spine applications. Pegasus Biologics, Inc. was founded in 2003 and is based in Irvine, California. As of July 17, 2009, Pegasus Biologics, Inc. operates as a subsidiary of Synovis Life Technologies Inc.

Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.

iScience Surgical, Inc. is a privately-held company founded in 1999. It is developing high resolution imaging systems and microsurgical instruments for the treatment of glaucoma. The Company's products are designed to complement existing glaucoma surgical techniques and serve as a platform for a new generation of minimally invasive procedures. Glaucoma is a sight threatening circulatory disorder of the eye that affects approximately 4.2 million Americans and 69 million people worldwide. More than $2 billion is spent annually on glaucoma medications and treatments worldwide, the majority of which are unable to restore the eye's natural drainage process.

Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

SpinalMotion is a private company focused on preserving spinal motion for patients suffering from degenerative disc disease. Founded in 2004, the company specializes in the development of innovative artificial disc implants that utilize proprietary Kineflex Technology, designed to maintain the natural movement of the spine while offering low wear and improved longevity. Since obtaining FDA approval in 2005 to conduct clinical trials for lumbar and cervical artificial discs in the United States, SpinalMotion has built on its international clinical experience to enhance patient outcomes. The company has attracted investment from notable partners, including Southern Medical, Three Arch Partners, Skyline Ventures, and MedVenture Associates, to further its mission of enabling patients to lead pain-free and healthy lives.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Reliant Technologies specializes in advanced laser treatments, particularly focusing on their proprietary Fraxel™ Laser Treatment. Founded in 2001 by a team of leading laser scientists, clinicians, and business executives, the company aims to redefine the standards of care in dermatology. Reliant's innovative technology platform addresses the challenges associated with aging and sun-damaged skin, moving beyond traditional, bulky laser systems. The company is committed to delivering effective solutions that enhance patient outcomes and streamline the treatment process, establishing a new paradigm in laser medicine.

VisionCare Ophthalmic Technologies, Inc. is a specialty medical device company based in Saratoga, California, focused on the research, development, manufacture, and marketing of innovative implantable ophthalmic devices. The company primarily aims to enhance vision and quality of life for individuals suffering from untreatable retinal disorders, particularly end-stage age-related macular degeneration (AMD), which is a leading cause of blindness among older Americans. VisionCare's flagship product is the Implantable Miniature Telescope, the first FDA-approved device designed to improve vision in patients with advanced AMD. This telescope implant is a critical component of the CentraSight treatment program, which guides patients through the processes of diagnosis, surgical evaluation, and postoperative care. Founded in 1997, VisionCare is dedicated to helping patients reconnect with their daily lives and activities through its advanced visual prosthetic technologies.

AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

NeuroBionics Corp. researches and develops medical devices for the treatment of neurological disorders such as Parkinson’s disease, epilepsy, obesity, and depression.

Concuity is a prominent provider of revenue cycle management software and services, focusing on contract profitability, compliance, denial management, and overall revenue process improvement for healthcare organizations. The company offers a fully web-based and scalable solution that enables these organizations to gain visibility and control over their revenue management processes. By facilitating the creation and negotiation of fair contracts, ensuring compliance with contractual obligations, and assisting in the identification and recovery of underpaid and denied accounts, Concuity enhances the efficiency of revenue management. Their solutions are customized to incorporate unique business rules and payer terms, allowing clients to better manage their revenue throughout its lifecycle.

Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.

Vascular Architects, Inc. specializes in designing, developing, manufacturing, and marketing medical devices aimed at treating vascular stenoses, occlusions, and non-vascular obstructions, with a particular focus on peripheral vascular disease. Founded in October 1997 by Dr. Thomas J. Fogarty, a distinguished surgeon and inventor, the company has established itself within the medical device industry by creating innovative surgical products for various markets, including cardiovascular and urology. Vascular Architects develops intraoperative vascular instruments such as Doppler probes and medical oxygen sensors, which are utilized across multiple surgical specialties. The company benefits from the expertise of a highly experienced management team and has engaged key opinion leaders from the interventional and vascular surgery communities to contribute to its Scientific Advisory Board.

Vitra Bioscience, a venture-backed biotechnology company, is developing novel technologies for comprehensive cellular analysis. The Company’s strategic objective is to create breakthrough solutions that enable users to acquire more informative data in less time, allowing for better decision-making. By applying modern imaging technology with proprietary consumables and software, Vitra Bioscience intends to develop and commercialize products that turn serial steps into parallel ones providing users with a complete tool set for their individual research needs.

LipoSonix, Inc. operates as a medical device company. The company develops non-invasive body sculpting products for aesthetic applications. The company was founded in 1999 and is based in Bothell, Washington. As of July 1, 2008, LipoSonix, Inc. operates as a subsidiary of Medicis Pharmaceutical Corp.

Evalve, Inc. engages in the design, development, manufacture, and marketing of devices that enable the repair of cardiac valves. It provides a non-surgical mitral valve repair system consisting of a steerable guide catheter, a clip delivery system, and an implant device that is used by interventional cardiologists to reduce mitral regurgitation. The company was incorporated in 1999 and is based in Menlo Park, California.

Coalescent Surgical, Inc. develops advanced technology for blood vessel anastomoses. Its surgical's U-CLIP anastomotic device enables heart surgeons to create anastomoses without tying knots or managing sutures.